![Robert Petit](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 428 000 $ al 31/05/2026
Robert G.
Petit is currently Senior VP & Head-Early Clinical Development at Orionis Biosciences, Inc. since 2022.
He is Chief Medical & Scientific Officer at OS Therapies, Inc. since 2019.
He is Principal at RGP Biotech, LLC since 2019.
Formerly, Dr. Petit was Director-Medical Strategy at Bristol Myers Squibb Co. from 2005 to 2010.
He was Vice President-Clinical Development at MGI PHARMA, Inc. and Aesgen, Inc. He served as Chief Scientific Officer & Executive VP at Advaxis, Inc. from 2010 to 2019.
He was Chief Scientific Officer at CTx Operations, Inc. and Carisma Therapeutics, Inc. in 2019.
Education includes undergraduate studies at Indiana State University and a doctorate from The Ohio State University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 22/01/2026 | 200.000 ( 0,45 % ) | 428 000 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| OS THERAPIES INCORPORATED | Director Técnico/Científico/I+D | 01/09/2019 |
RGP Biotech, LLC | Corporate Officer/Principal | 01/06/2019 |
Orionis Biosciences, Inc.
 Orionis Biosciences, Inc. Packaged SoftwareTechnology Services Offers protein interaction platform with direct applications in the discovery of new therapeutics | Corporate Officer/Principal | 01/03/2022 |
| Empresas | Cargo | Fin |
|---|---|---|
CTx Operations, Inc.
 CTx Operations, Inc. BiotechnologyHealth Technology Develops macrophage-based immunotherapeutic for treatment of cancer | Director Técnico/Científico/I+D | 01/12/2019 |
| CARISMA THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 01/12/2019 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/2010 |
Aesgen, Inc.
 Aesgen, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Corporate Officer/Principal | - |
MGI PHARMA, Inc.
 MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology Develops. manufactures & markets pharmaceutical and medical products for therapeutic markets | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 11 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
MGI PHARMA, Inc.
MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology Develops. manufactures & markets pharmaceutical and medical products for therapeutic markets | Health Technology |
Aesgen, Inc.
Aesgen, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Indiana State University
 Indiana State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Advaxis, Inc.
 Advaxis, Inc. Pharmaceuticals: MajorHealth Technology Develops immunotherapies for cancer and infectious diseases | Health Technology |
The Ohio State University
 The Ohio State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Orionis Biosciences, Inc.
Orionis Biosciences, Inc. Packaged SoftwareTechnology Services Offers protein interaction platform with direct applications in the discovery of new therapeutics | Technology Services |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology Develops macrophage-based immunotherapeutic for treatment of cancer | Health Technology |
OS Therapies, Inc.
 OS Therapies, Inc. BiotechnologyHealth Technology Operates as a clinical stage therapeutic company engages in development and commercialization of treatments for osteosarcoma | Health Technology |
Carisma Therapeutics, Inc.
 Carisma Therapeutics, Inc. BiotechnologyHealth Technology Develops novel chimeric antigen receptor macrophage and CAR-monocyte technology treatment of non-muscle invasive bladder cancer | Health Technology |
RGP Biotech, LLC |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
